Nasdaq-listed FSD Pharma To Advance Psychedelics Pipeline With $9 Million Acquisition Of Lucid Psycheceuticals

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE), a life sciences holding company looking at cannabinoid and psychedelic-based medicines, announced it is entering a definitive agreement to acquire Lucid Psycheceuticals Inc. 

Lucid is a psychedelic pharmaceutical company focused on developing therapies to treat neurodegenerative diseases and mental health disorders.

The all-stock transaction will include 4.5 million Class B subordinate voting shares of FSD Pharma, valued at approximately $9 million.

As part of the deal, Lucid’s co-founder and CEO, Dr. Lakshmi Kotra, will lead FSD Pharma’s drug development pipeline in psychedelics and medical …

Full story available on Benzinga.com

More Nasdaq-listed FSD Pharma To Advance Psychedelics Pipeline With $9 Million Acquisition Of Lucid Psycheceuticals